Client Services : 949-340-7598
General & Sales : 949-472-8000
Study Management : 949-472-8080

Posters & Presentations

2017
Rexahn and Mosaic Laboratories

Kim DJ, George C, Lee YB, Ahn CH, Frank J, Mazhari R, Dauffenbach LM, Olsen EP

Evaluation of UCK2 Protein Expression as a Potential Predictive Biomarker of RX-3117. AACR Meeting.

POSTER
2017
Mosaic Laboratories

Dauffenbach LM, Sia GC, Zheng J, Jun N, Olsen EP, Kerfoot CA.

Multiplex Immunohistochemical Staining of PD-L1, PD-1, CD3, CD4, CD8, CD68, FoxP3, and Ki-67 and Image Analysis of Tumor and Invasive Margin in Human FFPE NSCLC Tissue. AACR Meeting.

POSTER
2017
Mosaic Laboratories

Dauffenbach LM, Sia GC, Zheng J, Jun N, Olsen EP, Kerfoot CA.

Characterization of M2 Macrophage Subtype Content in Cancer and Normal Tissues. AACR Meeting.

POSTER
2016
BMS and Mosaic Laboratories (Referenced in Acknowledgements)

Hussein M, Wilks S, Monte M, Richards DA, Goldschmidt JH, Waterhouse D, Wang L, Yusko E, Emerson R, Taverna DM, Desai K, Mousses S, Qi Z, Hipp JD, Robins H, Kulig K, Batenchuk C.

Characterization of the T-Cell Receptor Repertoire in Extensive-Disease Small Cell Lung Cancer. AACR Meeting.

POSTER
2016
3-V Biosciences and Mosaic Laboratories (Referenced in Acknowledgements)

O’Farrell M, Heuer T, Grimmer K, Crowley R, Waszczuk J, Fridlib M, Ventura R, Rubio C, Lai J, Panda A, Buckley D, McCulloch W, Kemble G.

FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS mutant NSCLC patients in a Phase 1 study. AACR Meeting.

POSTER
2016
Celldex and Mosaic Laboratories (Referenced in Methods)

Halim A, Bagley RG, Dauffenbach LM, Olsen EP, Keler T.

IHC and RT-PCR Assays for Detection of Cancer Antigen NY-ESO-1 in Human Tissues. AACR Meeting.

POSTER
2016
Celldex and Mosaic Laboratories (Referenced under IHC Images)

Halim A, Bagley RG, Keler T.

Phase 1 results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events. AACR Meeting.

POSTER
2016
Celldex and Mosaic Laboratories (Referenced in Methods)

Halim A, Bagley RG, Keler T.

Glycoprotein NMB (gpNMB) Overexpression is Prevalent in Human Cancers: Pancreatic Cancer, Non-Small Cell Lung Cancer, Head and Neck Cancer, and Osteosarcoma. AACR Meeting.

POSTER
2015
Mosaic Laboratories

Dauffenbach LM, Sia GC, Cash PA, Girees SK, Lim RS, Zheng J, Olsen EP, Kerfoot CA.

Optimization of an Assay for the Detection of PD-L1 by Immunohistochemistry in Formalin-Fixed, Paraffin-Embedded Human Tissue and Cell Lines. AACR Meeting.

POSTER
2014
Mosaic Laboratories

McNutt M, Rimm D, Kerfoot CA, Thompson C.

Antibody Validation Roundtable: Specificity + Sensitivity + Reproducibility = Validation. Science Webinar.

PRESENTATION
2014
Mosaic Laboratories

Dauffenbach LM, Sia GC, Cash PA, Girees SK, Lim RS, Zheng J, Olsen EP, Richeh R, Kerfoot CA.

Optimization of an Assay for the Detection of Phosphorylated FAK by Immunohistochemistry in Formalin-Fixed, Paraffin-Embedded Human Tissue and Cell Lines. AACR Meeting.

POSTER
2014
Mosaic Laboratories

Dauffenbach LM, Sia GC, Cash PA, Girees SK, Lim RS, Zheng J, Olsen EP, Kerfoot CA.

Combination of PI3K and MEK Inhibitor Chemosensitivity in Human Tumor Explants and Cell Lines using the Mosaic Blue Assay and Relationship to Biomarkers by Immunohistochemistry. AACR Meeting.

POSTER
2013
Mosaic Laboratories

Dauffenbach LM, Cash PA, Sia GC, Girees SK, Lim RS, Zheng J, Olsen EP, Kerfoot CA.

Evaluation of MEK Inhibitor Chemosensitivity in Human Tumor Explants using the Mosaic Blue Assay and Relationship to Biomarkers by Immunohistochemistry. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

POSTER
2013
Mosaic Laboratories

Dauffenbach LM, Cash PA, Sia GC, Girees SK, Lim RS, Zheng J, Olsen EP, Kerfoot CA.

Evaluation of PI3K Inhibitor Chemosensitivity in Human Tumor Explants using the Mosaic Blue Assay™ and Relationship to Biomarkers by Immunohistochemistry. AACR meeting.

POSTER
2012
Bayer Healthcare Pharmaceuticals, Inc. and Mosaic Laboratories

Jeffers M, Dauffenbach LM, Peña C, Lathia C, Bhargava A, Kerfoot CA.

Comparison of Commercially Available Phosphorylated ERK Antibodies for Immunohistochemical Biomarker Analysis. AACR meeting.


POSTER
2012
Pathway Therapeutics and Mosaic Laboratories

O’Farrell M, Ventura R, Tai A, Matthews DJ.

The PI3K/mTOR Inhibitor PWT33597 Regresses 786-0 Renal Xenografts. AACR meeting.

POSTER
2011
Daiichi Sankyo and Mosaic Laboratories

Halim A, Dauffenbach LM, Kerfoot CA, Stull WR, Zwick-Wallasch E, Scheyer R and Senaldi G.

Immunohistochemical Analysis of HB-EGF Expression in Breast, Colon, Gastric, Hepatocellular, Lung, Ovarian, Pancreatic and Prostate Cancer. AACR meeting.

POSTER
2010
Merck & Co. and Mosaic Laboratories

Sun A, Lam RL, Pavlick AC, Harman A, Iannone R, Herman G, Dauffenbach LM, Kerfoot CA, Huang P, Bergstrom DA.

A Phase 1b Study to Evaluate Induction of pCDC2 in Skin Biopsies from Patients with Solid Tumors Treated with DNA-damaging Chemotherapy. AACR meeting.

POSTER
2010
Mosaic Laboratories

Kerfoot CA , Girees SK and Dauffenbach LM.

Multispectral Imaging of Chromogenic Multiplex IHC Assays as an Alternative to Fluorescent Methods. AACR meeting.

POSTER
2010
Bayer Healthcare Pharmaceuticals, Inc., Northeast Bioanalytical Labs and Mosaic Laboratories

Jeffers M, Dauffenbach LM, Bhargava A, Lathia C, Kerfoot CA.

Comparison of Commercially Available Phospho-AKT [Ser473] Antibodies for Immunohistochemical Biomarker Analysis. AACR meeting.

POSTER
2009
Ascenta and Mosaic Laboratories

MacVicar G, Greco FA, Reeves J, Maleski J, Holmlund J, Leopold L.

An Open-Label, Multicenter, Phase I/II Study of AT-101 in Combination with Docetaxel and Prednisone in Men with Castrate Resistant Prostate Cancer. ASCO Meeting.

POSTER
2009
Ascenta and Mosaic Laboratories

Poiesz B, Reeves J, McNulty J, Maleski J, Holmlund J, Leopold L.

Preliminary Report of an Open-Label, Multicenter, Phase I/II Study of AT-101 in Combination with Docetaxel and Prednisone in Men with Docetaxel Refractory Prostate Cancer. ASCO Meeting.

POSTER
2009
Ascenta and Mosaic Laboratories

Reeves J, McNulty W, Thomas G, MacVicar G, Maleski J, Leopold L.

Preliminary Report of an Open-Label, Multicenter, Phase I/II Study of AT-101 in Combination with Docetaxel and Prednisone in Men with Docetaxel Refractory Prostate Cancer. ASCO Genitourinary Cancers Symposium.

POSTER
2009
Cylene and Mosaic Laboratories

Drygin D, Bliesath J, Ho C, Siddiqui-Jain A, Streiner N, Chua P, Pierre F, Omori M, O’Brien S, Schwaebe M, Rice WG, Anderes K.

Discovery and characterization of CX-4945, a selective orally bioavailable small molecule inhibitor of protein kinase CK2: Phase 1 initiated. AACR Meeting.

POSTER
2009
Cylene and Mosaic Laboratories

Drygin D, Bliesath J, Ho C, Siddiqui-Jain A, Streiner N, Chua P, Pierre F, Omori M, O’Brien S, Schwaebe M, Rice WG, Anderes K.

CX-4945, a small molecule inhibitor of CK2, inhibits angiogenesis by affecting the vascular endothelium and suppressing hypoxia-activated Hif-1α transcription. AACR Meeting.

POSTER
2009
SuperGen and Mosaic Laboratories

Kanekal S, Lei S, and Redkar S.

MP-470, a Rad51 Suppressor and Multiple TK Inhibitor, Retards Growth of Primary Human Glioblastoma Multiforma (GBM) Cells and Synergizes Eect of Temozolomide. AACR Meeting.

POSTER
2009
Mosaic Laboratories

Dauffenbach LM, Girees SK, Cash PA, Sia G, Stull WR, Kerfoot CA.

Aurora A, pMet, pAKT, and pSTAT3 as predictive and pharmacodynamic biomarkers of EGFR inhibitor response in colon and lung cancer cell lines. AACR Meeting.

POSTER
2009
Mosaic Laboratories

Kerfoot CA.

Multiplex Immunohistochemistry and Multispectral Imaging: Expanding the Repertoire for Clinical Trial Monitoring. USCAP Meeting.

2008
Mosaic Laboratories

Kerfoot CA, Stull WR, Girees SK, Cash PA, Dauffenbach LM.

Mosaic Blue Assay: Erlotinib and gefitinib chemosensitivity in non-small cell lung cancer explants and the relationship to EGFR and other biomarkers. AACR meeting.

POSTER
2007
Mosaic Laboratories

Kerfoot CA , Girees SK, Dauffenbach LM.

Multiplex Immunohistochemical characterization of aurora A and aurora B in breast, ovarian, non-small cell lung, and colon cancer. AACR meeting.

POSTER
2007
Mosaic Laboratories

Kerfoot CA and Dauffenbach LM.

Quantitative multiplex chromogenic immunohistochemistry. Tucson Symposium.

POSTER
2006
Mosaic Laboratories

Dauffenbach LM and Kerfoot CA.

Multiplexing immunohistochemical assays of clinical importance for epidermal growth factor receptor inhibitors. AACR meeting.

POSTER
2006
CRi Inc. and Mosaic Laboratories

Kerfoot CA, Endlich ME, Levenson RM.

Multispectral analysis of multiplex immunohistochemical stains. USCAP meeting.

POSTER
2006
CRi Inc. and Mosaic Laboratories

Levenson RM, Mansfield JR, Kerfoot CA.

Multispectral imaging enables double-nuclear and double-membrane immunohistochemistry. International Academy of Pathology Meeting.

2006
CRi Inc. and Mosaic Laboratories

Mansfield JR, Kerfoot CA, Levenson RM,

Multiplexing molecular markers with multispectral imaging. 7th Joint Meeting of the Histochemical Society and the Japan Society of Histochemistry and Cytochemistry.

2006
CRi Inc. and Mosaic Laboratories

Mansfield J, Kerfoot CA, Levenson RM.

Multiplexing molecular markers with multispectral imaging. Tucson Symposium.

POSTER